海翔药业(002099) - 2019 Q1 - 季度财报
HISOARHISOAR(SZ:002099)2019-04-22 16:00

Financial Performance - The company's revenue for Q1 2019 was ¥831,903,896.72, representing a 36.21% increase compared to ¥610,754,044.64 in the same period last year[9]. - Net profit attributable to shareholders was ¥202,484,692.73, a significant increase of 352.29% from ¥44,768,449.76 year-on-year[9]. - The net profit after deducting non-recurring gains and losses was ¥193,305,262.65, up 341.53% from ¥43,780,799.03 in the previous year[9]. - Basic and diluted earnings per share were both ¥0.13, reflecting a 333.33% increase from ¥0.03 in the same period last year[9]. - The weighted average return on equity rose to 3.69%, an increase of 2.82 percentage points from 0.87% year-on-year[9]. - The company reported a 346.17% increase in selling expenses, totaling ¥23,791,618.10, primarily due to increased commissions[22]. - The company expects a net profit growth rate of 63.13% to 81.26% for the first half of 2019 compared to the previous year[28]. Assets and Liabilities - Total assets at the end of the reporting period were ¥7,119,310,130.14, a 1.19% increase from ¥7,035,373,344.57 at the end of the previous year[9]. - Net assets attributable to shareholders decreased by 5.13% to ¥5,113,762,486.64 from ¥5,390,549,932.23 at the end of the previous year[9]. - Total current assets as of March 31, 2019, amounted to CNY 3,789,241,092.27, an increase from CNY 3,733,595,006.61 in the previous period[38]. - Total liabilities increased to CNY 2,005,547,643.50 from CNY 1,644,823,412.34, indicating a rise of about 22%[41]. - The equity attributable to shareholders decreased to CNY 5,113,762,486.64 from CNY 5,390,549,932.23, a decline of approximately 5%[44]. - Total liabilities rose to ¥1,192,045,238.23, compared to ¥692,654,284.96, indicating an increase of 72.3%[54]. Cash Flow - The net cash flow from operating activities was ¥121,163,063.50, down 24.98% from ¥161,505,950.17 in the same period last year[9]. - The company’s cash flow from financing activities decreased by 64.00% to -¥109,102,697.03, primarily due to reduced loan repayments[22]. - The net cash flow from investment activities was ¥295,643,069.92, a significant increase of 3464.49% from ¥8,294,108.93 in the previous year[22]. - The net cash flow from operating activities was -3,618,161.29 CNY, a significant decrease from 126,081,445.70 CNY in the previous period[78]. - Cash outflow from operating activities totaled 419,973,625.84 CNY, compared to 919,814,796.24 CNY in the previous period[78]. Expenses - Total operating costs amounted to ¥604,854,497.68, up from ¥550,796,225.35, reflecting a year-over-year increase of 9.8%[55]. - The company’s income tax expense rose by 120.00% to ¥34,208,068.22, reflecting an increase in profits[22]. - Research and development expenses for the quarter were ¥30,305,725.69, compared to ¥24,686,729.44, marking an increase of 22.5%[55]. - Financial expenses decreased by 84.63% to ¥13,016,511.51, attributed to increased exchange gains from the appreciation of the US dollar[22]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 65,663[13]. - The company reported a decrease in unallocated profits to CNY 968,222,301.73 from CNY 1,232,481,918.50, a decline of approximately 21%[44]. - The company received government subsidies amounting to ¥13,089,157.28 during the reporting period[9]. Other Financial Metrics - The company recorded a credit impairment loss of ¥5,572,318.53, a 1468.88% increase, due to higher sales revenue and increased accounts receivable[22]. - The company reported a significant decrease in employee compensation payable, which fell to ¥4,013,448.98 from ¥6,439,699.82, a reduction of 37.5%[51]. - The total comprehensive income for the current period was ¥202,839,941.60, compared to ¥44,855,448.57 in the previous period[61]. - The company’s other income increased to ¥13,089,157.28 from ¥1,449,126.22, a substantial rise of 804.5%[55].